LENZ Cuts 75% of Staff, CEO Out Dec. 1 as 2027 Opex Target Falls to $70-75M
LENZ is trading near its 52-week low of $3.06 (0.0% above the low).
Summary
LENZ reported Q3 VIZZ sales of $2.6 million, up about 50% sequentially, alongside a reorganization that cuts headcount by roughly 75% and targets $70-75 million of 2027 operating expenses. CEO Eef Schimmelpennink steps down December 1, with CFO Dan Chevallard taking over as interim CEO.
Key Events · Executive and Board Changes · LENZ
-
Headcount Cut ~75% to ~40 Employees
The board approved a reorganization decreasing headcount by approximately 75% to approximately 40 full-time employees, with about $5 million of one-time severance and termination charges, substantially all in Q4 2026.
-
2027 Opex Target Cut More Than Half
LENZ targets approximately $70 million to $75 million of 2027 operating expenses excluding stock-based compensation, versus $120.2 million of SG&A in the first nine months of 2026 alone.
-
CEO Out December 1; CFO Takes Interim Role
Eef Schimmelpennink transitions from President and CEO effective December 1, 2026 and leaves the board; CFO Dan Chevallard becomes Interim President and CEO while keeping his CFO, principal financial and principal accounting officer roles. The board shrinks to five.
-
Q3 VIZZ Sales $2.6M, Up ~50% Sequentially
Product sales were $2.6 million on over 38,000 paid prescriptions, up approximately 50% and 51% over Q2 2026; license revenue added $0.8 million and net loss was $31.0 million.
Analysis · LENZ · Life Sciences
LENZ is shrinking to roughly 40 employees and targeting $70 million to $75 million of 2027 operating expenses excluding stock-based compensation — less than half of what it was running — after burning $120.2 million of SG&A in the first nine months of 2026 against just $6.0 million of product sales. That is a survival-driven pivot: the company keeps $197.3 million of cash and securities, so the cuts buy years of runway rather than weeks, but they also concede that the broad national DTC campaign did not pay for itself. The CEO who built the company from Series A through FDA approval exits December 1, leaving the CFO as interim chief while the board shrinks to five. Q3 product sales of $2.6 million, up about 50% from Q2 on over 38,000 paid prescriptions, are the one part of the story that argues the drug is finding a market.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LENZ was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $3.06 to $32.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.